Targeting CD38 in Antibody-Mediated Rejection.
Katharina A Mayer, Klemens Budde, Matthias Diebold...
https://pubmed.ncbi.nlm.nih.gov/40444214/Actively Recruiting
Led by Takeda · Updated on 2026-11-04
171
Participants Needed
124
Research Sites
N/A
Total Duration
Researchers are studying chronic primary immune thrombocytopenia ITP, a condition where the immune system mistakenly destroys platelets, leading to easier bruising and bleeding due to low platelet counts. The trial aims to evaluate whether mezagitamab, given as a subcutaneous injection, can maintain stable platelet levels in adults with ITP compared to a placebo. This Phase 3 study is randomized, double-blind, and placebo-controlled to thoroughly assess mezagitamabs effects. Participants will receive either mezagitamab or a matching placebo injection once weekly. The dosing schedule includes 8 weeks of weekly injections, followed by an 8-week break, and then another 8 weeks of weekly injections, totaling up to 6 months of treatment. Those who complete this study or do not respond by week 16 may have the option to join a continuation study to receive open-label mezagitamab if eligible. During the study, participants will visit the clinic multiple times for assessments. Researchers will monitor platelet counts regularly and evaluate responses using measures such as the percentage of participants with durable platelet response up to week 24. Additional assessments include symptom questionnaires, fatigue scores, bleeding events, and monitoring of mezagitamab levels and antibodies. The study also observes safety and treatment effects through week 24 and beyond as needed.
CONDITIONS
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
T
Takeda Contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Takeda
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Mezagitamab | Placebo | Current Standard Care |
|---|---|---|---|
| What it is | An investigational subcutaneous antibody called mezagitamab being tested for chronic primary ITP | A matching placebo injection administered under the same conditions | Thrombopoietin receptor agonists or rituximab are commonly used second‑line treatment options for adult patients with chronic primary ITP |
| Role in trial | Investigational treatment arm under study | Comparator control arm receiving placebo injection | Not used in this trial; represents typical clinical options outside the study |
| Primary purpose | Test whether mezagitamab leads to a durable platelet response | Control arm for comparing platelet response rates | To illustrate average clinical platelet response under available second‑line therapies |
| Administration method | Injected subcutaneously under study protocol | Matching subcutaneous placebo injection | Administered per usual clinical practice, typically oral or IV/subcutaneous depending on agent |
| Evidence status | Efficacy is under evaluation; durable platelet response is being measured up to Week 24 | Efficacy comparator for measuring treatment effect | Established response rates exist in other studies and reflected in guidelines |
| Important limitations | Safety and long‑term durability beyond 24 weeks are not yet known | Placebo does not reflect active therapy; no clinical benefit expected | Comparative effectiveness may vary by agent, patient characteristics, and guideline strength |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 6 months
Participants receive weekly injections of mezagitamab or a matching placebo under the skin following a schedule of 8 weeks on treatment, 8 weeks off, then 8 more weeks on treatment.
Multiple clinic visits during treatment
Duration - Varies by participant
Participants who complete the study or do not respond by week 16 may have the opportunity to join a continuation study to receive open-label mezagitamab if eligible.
Visits depend on continuation study protocol
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Katharina A Mayer, Klemens Budde, Matthias Diebold...
https://pubmed.ncbi.nlm.nih.gov/40444214/Takeda
Lead Sponsor